


MDM2/4-p53-IN-2

Cat. No.:	HY-151170
Molecular Formula:	C ₂₅ H ₁₇ Cl ₃ FN ₃ O ₃
Molecular Weight:	532.78
Target:	MDM-2/p53; Apoptosis
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	MDM2/4-p53-IN-2 (2q) is a potent dual MDM2/MDM4 inhibitor and p53 activator with the IC ₅₀ values of 70.7 nM for MDM2-p53 and 81.4 nM for MDM4-p53 complexes. MDM2/4-p53-IN-2 regulates the cell cycle, induces cell apoptosis and has anticancer activity ^[1] .																
In Vitro	<p>MDM2/4-p53-IN-2 (2q) (1-100 μM, 96 h) can inhibit the proliferation of cancer cells and induce cell apoptosis by targeting the G0/G1 cell cycle in a dose-dependent manner^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Human cancer cell lines HCT116, SJSA-1, MCF-7, LNCaP, human embryonic kidney epithelial cell line HEK 293T</td> </tr> <tr> <td>Concentration:</td> <td>1-100 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 hours</td> </tr> <tr> <td>Result:</td> <td>Showed anti-proliferative activity of HCT116 with an IC₅₀ value of 18.0 μM. Showed well inhibition of cell viability against SJSA-1, MCF-7, LNCaP cells, all below 40%. Reduced cell viability of HEK 293T cells by 24%.</td> </tr> </table> <p>Apoptosis Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>SJSA-1 cell lines</td> </tr> <tr> <td>Concentration:</td> <td>15 and 22.5 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>96 hours</td> </tr> <tr> <td>Result:</td> <td>Increased LDH release by 1.3-fold and 1.6-fold at concentrations of 15 μM and 22.5 μM, respectively. Caused a decrease in SJSA-1 cells, a significant decrease in cell growth and an increase in the number of early and late stage apoptotic cells at 22.5 μM. Induced a significant accumulation of G0/G1 phase cells with a percentage of 67.5% at 15 μM and 82.2% at 22.5 μM, while reducing the percentage of S and G2/M phase cells.</td> </tr> </table>	Cell Line:	Human cancer cell lines HCT116, SJSA-1, MCF-7, LNCaP, human embryonic kidney epithelial cell line HEK 293T	Concentration:	1-100 μM	Incubation Time:	48 hours	Result:	Showed anti-proliferative activity of HCT116 with an IC ₅₀ value of 18.0 μM. Showed well inhibition of cell viability against SJSA-1, MCF-7, LNCaP cells, all below 40%. Reduced cell viability of HEK 293T cells by 24%.	Cell Line:	SJSA-1 cell lines	Concentration:	15 and 22.5 μM	Incubation Time:	96 hours	Result:	Increased LDH release by 1.3-fold and 1.6-fold at concentrations of 15 μM and 22.5 μM, respectively. Caused a decrease in SJSA-1 cells, a significant decrease in cell growth and an increase in the number of early and late stage apoptotic cells at 22.5 μM. Induced a significant accumulation of G0/G1 phase cells with a percentage of 67.5% at 15 μM and 82.2% at 22.5 μM, while reducing the percentage of S and G2/M phase cells.
Cell Line:	Human cancer cell lines HCT116, SJSA-1, MCF-7, LNCaP, human embryonic kidney epithelial cell line HEK 293T																
Concentration:	1-100 μM																
Incubation Time:	48 hours																
Result:	Showed anti-proliferative activity of HCT116 with an IC ₅₀ value of 18.0 μM. Showed well inhibition of cell viability against SJSA-1, MCF-7, LNCaP cells, all below 40%. Reduced cell viability of HEK 293T cells by 24%.																
Cell Line:	SJSA-1 cell lines																
Concentration:	15 and 22.5 μM																
Incubation Time:	96 hours																
Result:	Increased LDH release by 1.3-fold and 1.6-fold at concentrations of 15 μM and 22.5 μM, respectively. Caused a decrease in SJSA-1 cells, a significant decrease in cell growth and an increase in the number of early and late stage apoptotic cells at 22.5 μM. Induced a significant accumulation of G0/G1 phase cells with a percentage of 67.5% at 15 μM and 82.2% at 22.5 μM, while reducing the percentage of S and G2/M phase cells.																

REFERENCES

[1]. Margarida Espadinha, et al. Discovery of MDM2-p53 and MDM4-p53 protein-protein interactions small molecule dual inhibitors. Eur J Med Chem. 2022 Aug 5;241:114637.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA